Skip to Content
Merck
  • Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator.

Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator.

Journal of medicinal chemistry (2006-10-13)
Arjan van Oeveren, Mehrnouch Motamedi, Neelakandha S Mani, Keith B Marschke, Francisco J López, William T Schrader, Andrés Negro-Vilar, Lin Zhi
ABSTRACT

The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators.

MATERIALS
Product Number
Brand
Product Description

Supelco
Testosterone, VETRANAL®, analytical standard
Supelco
Testosterone solution, 1.0 mg/mL in 1,2-dimethoxyethane, drug standard
Sigma-Aldrich
5α-Androstan-17β-ol-3-one, ≥97.5%
Supelco
5α-Androstan-17β-ol-3-one, VETRANAL®, analytical standard